| Literature DB >> 27838171 |
Tihomir Tomašič1, Matic Mirt2, Michaela Barančoková2, Janez Ilaš2, Nace Zidar2, Päivi Tammela3, Danijel Kikelj2.
Abstract
Development of novel DNA gyrase B inhibitors is an important field of antibacterial drug discovery whose aim is to introduce a more effective representative of this mechanistic class into the clinic. In the present study, two new series of Escherichia coli DNA gyrase inhibitors bearing the 4,5-dibromopyrrolamide moiety have been designed and synthesized. 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazole-2,6-diamine derivatives inhibited E. coli DNA gyrase in the submicromolar to low micromolar range (IC50 values between 0.891 and 10.4μM). Their "ring-opened" analogues, based on the 2-(2-aminothiazol-4-yl)acetic acid scaffold, displayed weaker DNA gyrase inhibition with IC50 values between 15.9 and 169μM. Molecular docking experiments were conducted to study the binding modes of inhibitors.Entities:
Keywords: Antibacterial; DNA gyrase; Docking; Inhibitor; Thiazole
Mesh:
Substances:
Year: 2016 PMID: 27838171 DOI: 10.1016/j.bmc.2016.10.038
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641